Product Description
Yttrium Y 90 Anti-CD45 Monoclonal Antibody (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00618696)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Antibody
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Masonic Cancer Center, University of Minnesota
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Preleukemia|Myelodysplastic Syndrome|Acute Lymphoid Leukemia|Chronic Lymphoid Leukemia|Acute Myeloid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Chronic Myeloid Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2005LS039 | P1 |
Terminated |
Myelodysplastic Syndrome|Preleukemia |
2007-12-01 |
|
| 2010LS030 | P1 |
Terminated |
Chronic Myeloid Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Acute Myeloid Leukemia|Acute Lymphoid Leukemia|Preleukemia|Chronic Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Myelodysplastic Syndrome |
2014-07-01 |